Recombinant Human IFNB Protein，His

Interferon beta (IFN-β) is a cytokine with significant therapeutic potential, particularly in the treatment of multiple sclerosis (MS) and certain viral infections. Its role in modulating immune responses has led to extensive research into its mechanism of action and clinical applications. Early studies identified IFN-β as a crucial player in the regulation of inflammatory processes, enhancing the body's defense against pathogens. The advent of recombinant DNA technology in the 1980s facilitated the production of IFN-β, allowing for a more consistent and efficient source compared to natural extraction from lymphocytes. This development has spurred the investigation of various recombinant forms of IFN-β, leading to the approval of several products for clinical use, such as Avonex and Rebif. Ongoing research focuses on understanding the pharmacokinetics, optimal dosing strategies, and potential side effects of IFN-β therapy. Additionally, scientists are exploring combination therapies, wherein IFN-β is used alongside other immunomodulatory agents to enhance therapeutic outcomes in MS and related conditions. The continuous evolution of IFN-β research reflects its enduring significance in both basic and translational medicine, aiming to improve patient outcomes and expand its utility in broader therapeutic contexts.